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in 2000 and later, 6 used reduced intensity conditioning. Two
patients had persistent disease, four died prior to 30 days post
transplant and it was assumed that all others achieved remission.
Four allogeneic and one autologous recipient relapsed, all within 3
years post transplant. For allogeneic transplants, the 5-year overall
survival probability was 48% with lower and upper bounds of 31%
and 65%, which is comparable to the ﬁnding of 47% in a recent
EBMT study [1]. Transplant related mortality at 100 days was
19.6%. There were 16 deaths in the ﬁrst year post transplant
among allogeneic and syngeneic recipients, from infection (7),
GVHD (4), organ failure (3) and persistent disease (2). Both au-
tologous recipients died, from septicaemia at 6 months and relapse
at 2.3 years post transplant. The ABMTRR is an important na-
tional data resource which enables accurate and timely analysis of
transplant activity and outcome, particularly for rare indications
that have relatively small numbers.
1. Guardiola P, et al. Allogeneic stem cell transplantation for
agnogenic myeloid metaplasia: a European Group for Blood and
Marrow Transplantation, Societe Francaise de Greffe de Moelle,
Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred
Hutchinson Cancer Research Center collaborative study. Blood.
1999;93:2831-2838.
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LOW INCIDENCE OF ACUTE GRAFT VERSUS HOST DISEASE AND RE-
DUCED EARLY MORTALITY IN CP-CML PATIENTS TRANSPLANTED US-
ING CSA, MTX AND MP AS IMMUNOPROPHYLAXIS
Funke, V.M., Setubal, D.C., Ruiz, J., Lima, D.H., Bonﬁm, C.M.,
Bitencourt, M.A., Zanis-Neto, J., de Medeiros, C.R., Pasquini, R.
Hospital de Clı´nicas-Federal University of Parana, Curitiba, Parana,
Brazil.
Signiﬁcant early transplant related mortality is one of the factors
that have impacted the reduction of transplants for CML, espe-
cially in the imatinib era. However, curative potential of bone
marrow transplantation has to be taken into consideration, espe-
cially for young high risk patients. Patients and Methods: We
report here long-term results from a single center experience of
166 patients submitted to bone marrow transplantation for chronic
phase CML from 1990 to 2004. All patients received marrow from
sibling HLA identical donors, and used BU  CY as the condi-
tioning regimen and cyclosporine, methotrexate and a short course
of MP (1 mg/kg/day from day 14 to day 28, then tapered 20%
per week) as immunoprophylaxis. Male: 92; female 74. Median age
was 33 years (range 6-51). Median duration of disease was 20
months (4-87). Univariate and multivariate analysis of risk factors
for survival were performed. Age, disease duration before trans-
plant, female donor  male patient, time of engraftment, acute
GVHD and chronic GVHD were analyzed risk factors. Results:
Mortality before day 100 was 8%. Grade III-IV acute GVHD
occurred in only 7% of the patients. From 153 patients who survived
more than 100 days, 63 (38%) developed extensive chronic graft-
versus-host disease. Median survival was 2498 days (58-5391). Overall
survival and estimated disease free survival in 14 years was 71%. Only
the presence of grade III-IV of acute and extensive chronic graft-
versus-host disease were identiﬁed as independent risk factors for
survival. Causes of death included: c-GVHD (13%), infections (9%)
and progressive disease (7%). Conclusions: The addition of MP to
the immunoprophylaxis regimen has effectively reduced the incidence
of grade III-IV acute GVHD and early transplant related mortality.
No inﬂuence was seen on chronic GVHD incidence, overall survival
or disease free survival.
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PREDICTIVE FACTORS AND IMPACT OF FULL DONOR T-CELL CHIMER-
ISM AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC
STEM CELL TRANSPLANTATION (ALLO-SCT)
Mohty, M.1, Avinens, O.2, Faucher, C.1, Furst, S.1, Viens, P.1,
Gastaut, J.-A.1, Eliaou, J.-F.2, Blaise, D.1 1Institut Paoli-Calmettes,
Marseille, France; 2CHU de Montpellier, Montpellier, France.
The kinetics of lineage-speciﬁc chimerism proved to be an im-
portant issue after RIC allo-SCT. Here, we investigated the impact
of different factors on the establishment of full donor CD3T cell
chimerism (TCC) in a series of 102 patients receiving RIC allo-
SCT from an HLA-identical sibling. 65 patients received an ATG-
based RIC regimen (ﬂudarabine, busulfan and ATG), 14 patients
received a low dose TBI-based RIC (2 Gy), while the remaining 23
patients received an association of ﬂudarabine, busulfan and total
lymphoid irradiation (TLI; 1.7 Gy). At day 30, 30% (95% CI,
21-39%) of patients achieved a full TCC in the peripheral blood.
At day 90, 77% (95% CI, 69-85%) had a full donor TCC. In
univariate analysis, none of the patient, graft, RIC type, or disease
characteristics could be predictive of establishment of an early full
donor TCC at day 30. However, the group of 31 patients who
achieved a full donor TCC by day 30, experienced a signiﬁcantly
higher incidence of grade 2-4 acute GVHD, in comparison to the
group of 71 patients who were still in mixed TCC at day 30
(cumulative incidence, 61% vs. 35%; P  .01). When looking for
predictive factors for full donor TCC at day 90, univariate analysis
showed that diagnosis category, the RIC type (ATG, TBI or
TLI-based RIC), a female donor, CD34 cell dose, and CD4 T
cell dose, were signiﬁcant or had a trend towards signiﬁcant asso-
ciation with establishment of full donor TCC by day 90. In mul-
tivariate analysis, a diagnosis other than a myeloid malignancy, was
the strongest parameter signiﬁcantly predictive of establishment of
full TCC at day 90 (P .007; OR 3.82; 95% CI, 1.4-10.1). Most
importantly, the delayed establishment of full donor TCC in pa-
tients with myeloid malignancies translated towards a worsened
PFS (P  .06) in the group of 15 patients who did not achieve full
donor TCC at day 90 as compared to the group of 26 patients who
achieved a full donor TCC. This worsened PFS was due to a
signiﬁcantly higher incidence of leukemia relapse among these 15
patients (6 relapses; 40%) as compared to none in the other group
of 26 patients (P  .002). Overall, we conclude that cautious
monitoring of the levels of donor TCC is mandatory after RIC
allo-SCT, because this can improve patient outcomes through
identiﬁcation of patients at risk for acute GVHD, and disease
progression, and guidance of early interventions with immunosup-
pressive drugs or DLI aimed at obviating these complications.
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PENTOSTATIN, TBI AND EXTRACORPOREAL PHOTOPHERESIS FOR RE-
DUCED-INTENSITY PREPARATION: SINGLE CENTER ADAPTATION OF
THE TUFTS EXPERIENCE
Abboud, C.N., Liesveld, J.L., Bernstein, S.H., Friedberg, J.,
Ifthikharuddin, J.J., Constine, L.S., Kaplan, K.L., Wedow, L.A.,
Nichols, D.D., Oliva, J., Etter, M., Phillips, G.L. James P Wilmot
Cancer Center, University of Rochester, Rochester, NY.
Conditioning regimens used in reduced intensity transplants are
designed to optimize immune suppression to allowing for prompt
engraftment and robust graft versus tumor effect. The Tufts reg-
imen (Miller KB, et al. Bone Marrow Transplant 2004;34:881) has a
reduced incidence of GVHD while demonstrating disease response
using extracorporeal photopheresis (ECP), pentostatin 4 mg/m2/
day 2 and a reduced dose of total body irradiation (TBI: 600 cGy
given in 3 fractions). We treated 45 patients with a minimum of 6
months follow up, median age of 55 years (27-67); 33 patients were
50 years or older; 25 received sibling and 20 an unrelated donor
(UD) transplant. All but one sibling transplant was a 6/6 match,
whereas 8/20 UD transplants involved mismatched loci. GVHD
prophylaxis consisted of tacrolimus and short course methotrexate
in 43, tacrolimus/MMF in 1 and tacrolimus/sirolimus in 1. Seven-
teen patients had AML, 3 MDS, 2 ALL, 2 CML, 11 CLL, 8 NHL,
1 HD and 1 lymphoplasmacytic lymphoma. Eight of the 45 had
prior stem cell transplantation. The median number of CD34
cells infused was 4.54 million/kg. Nine patients were transplanted
in CR or early disease phase. Five patients died before anticipated
neutrophil recovery, 2 had no neutrophil nadir and median time to
neutrophil engraftment was 14.5 days, and platelets recovered in
18.7 days. Donor chimerism at 30 days by VNTRs was 94% (range
34%-100%). The overall day 100 survival was 69% (31/45), with
80% (20/25) of sibling graft recipients alive and 55% (11/20) of
UD recipients still living. Twelve patients developed regimen
related toxicity. In ﬁve this manifested as ARDS or multiorgan
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failure with capillary leak syndrome, and 2 had renal failure. Ten
patients had disease resistance or relapse after transplant, and all
have expired. Overall survival to date is 42% (48% for sibling
transplants and 35% for UD) with a range of follow-up from 283
to 1366 days (median 535 days). Acute GVHD grade III or IV was
seen in only 3 patients. After day 100, 27% had extensive GVHD.
The best results were seen in AML or CLL in CR or early relapse
with chemosensitive disease, no AML patient in full blown relapse
survived. This regimen is well tolerated and offers a suitable plat-
form for reduced intensity allogeneic stem cell transplantation.
The beneﬁt(s) of ECP require further testing in the context of
improved radiation therapy, TBI versus TLI (total lymphoid irra-
diation).
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NON-MYELOABLATIVE ALLOGENEIC TRANSPLANTATION WITH ALE-
MTUZUMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE USING 3-6/6
HLA MATCHED DONORS
Rizzieri, D., Chute, J., Horwitz, M., Gasparetto, C., Sullivan, K.,
Long, G., Morris, A., Niedzwiecki, D., Nelson, C. Duke University
Medical Center, Durham, NC.
To broaden the proportion of patients able to undergo allogeneic
therapy, we have investigated the use of 3-6/6 HLA matched
family member donors in combination with donor T cell depletion
in a non-myeloablative preparative regimen. Methods: Seventy
ﬁve matched and 63 mismatched patients received ﬂudarabine 30
mg/m2 IV qd  4, cyclophosphamide 500 mg/m2 IV qd  4, and
alemtuzumab 20 mg IV qd  5 followed by infusion of donor stem
cells. In those with a matched donor, no other GVHD prophylaxis
was used. In those with a 3-5/6 HLA matched donor, mycophe-
nolate 1000 mg po BID was given to the ﬁrst 35 and cyclosporine
was added to the subsequent 28 for 6-8 weeks following transplan-
tation. Results: Patient diagnoses included lymphoma/myeloma
n  36, leukemia/MDS n  63, myeloﬁbrosis/aplasia n  10,
metastatic solid tumors n  29. The median age was 48 (17-70)
with a median follow up of approximately 20 months. Engraftment
occurred in 100% of matched recipients and 92% of mismatched
patients. Eight percent had secondary graft failure as well. Forty six
patients with a matched donor and 23 with a mismatched donor
also had a DLI (range 105-107 CD3 cells/kg). Grade III-IV acute
GVHD occurred in only 7/75 (7%) in the matched setting and
8/63 (13%) of patients. Four percent of matched and 15% of the
mismatched patients developed chronic GVHD and CMV reacti-
vation was common. One hundred day treatment related mortality
for both groups was 10%. Combining both matched and mis-
matched patients, only 12% entered in remission, though 76%
attained a CR. The most common cause of death remained pro-
gressive disease (42%) and GVHD (8%). Despite the high risk
nature of this group, 21 had aplastic anemia/myeloﬁbrosis or leu-
kemia in ﬁrst or second CR and no other available donor other
than their mismatched family member. This group had an encour-
aging 50% 3 year median survival. Phenotypic, spectratype and
TRECs analysis reveals robust recovery by 6 months following
transplantation from peripheral expansion of residual transplanted
T cells Conclusions: The results demonstrate reasonable toler-
ance and reliable engraftment using T cell depleted, 3-6/6 HLA
matched family member donors in a non-myeloablative setting
with low treatment related mortality and severe GVHD. The
future challenge will to be to develop strategies to improve im-
mune recovery to enhance immune-mediated graft-versus-tumor
effect and to minimize the risk of infections.
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THE RELATIONSHIP OF DAY 30 AND DAY 100 DONOR CHIMERISM TO
CLINICAL OUTCOMES FOLLOWING REDUCED-INTENSITY ALLOGENEIC
TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES
Michaelis, L.C., Lin, S.P., Joseph, L., Artz, A.S., Kline, J., Pollea, D.,
Stock, W., Rich, E., Jones, D., Casey, B., Del Cerro, P., Van Besien, K.
University of Chicago, Chicago, IL.
Background: We analyzed chimerism in unfractionated blood
samples of 94 patients enrolled in a prospective phase II trial of
allogeneic transplantation for hematologic malignancies. The aim
was to determine the relationship between chimerism and clinical
outcomes. Methods: All patients received ﬂudarabine, melphalan,
alemtuzumab, post-transplant tacrolimus and peripheral blood
stem cells from related or unrelated donors. PCR-based analysis of
ten polymorphic loci (VNTR) was performed on donor and recip-
ient unfractionated bone marrow aspirates and/or peripheral blood
samples prior to and on approximately day 30 and day 100 after
transplantation. The percentage of donor chimerism and the
change in chimerism between the two time points were examined
for effect on relapse, acute graft vs. host disease, chronic graft vs.
host disease, death, and time to these events. Results: A total of
39/94 (42%) relapsed and 47/94 (50%) have died with a median
follow up of 14 months (range: 1-40 months). Of the 94 patients,
22 had acute GVHD with a severity grading of between II and IV
and 15 experienced chronic GVHD. 86 (91%) of 94 patients had
samples collected for day 30, and 66 (70%) had samples collected
for day 100. The mean chimerism on day 30 samples was 93%
donor (95% CI: 90-97%). There was no signiﬁcant relationship
between the day 30 chimerism and acute GVHD, chronic GVHD,
relapse, death, or time to these events. The mean chimerism for the
66 subjects with available day 100 samples was 88% (95% CI:
83-92%). There was also no relationship found between the day
100 chimerism or its change from the day 30 and chronic GVHD,
relapse, death, or time to these events Conclusions: A ﬂudarabine,
melphalan and alemtuzumab conditioning regimen results in rapid
attainment of high rates of donor chimerism. The percentage of
donor chimerism in unfractionated cell populations did not corre-
late with clinical outcomes in this study. Analysis of T-cell subsets
may be more predictive and is currently being evaluated.
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PRIOR INVASIVE FUNGAL INFECTION DOES NOT PRECLUDE SUCCESS-
FUL ALLOGENEIC TRANSPLANTATION
Hill, B.T., Kondapalli, L., Artz, A., Smith, S., Odenike, O.,
Larson, R.A., Stock, W., Besien, K.V. University of Chicago Section of
Hematology-Oncology, Chicago, IL.
Prior invasive mold infection has historically been considered a
contra-indication for allogeneic stem cell transplantation because
of the high risk of fungal reactivation, and the limited efﬁcacy and
high toxicity of amphotericin-based drugs. Newer antifungal
agents with broad antifungal coverage and an excellent safety and
tolerability proﬁle have dramatically altered the management and
outcome of fungal infections. Here we present a series of 22
consecutive patients with hematologic malignancy and prior inva-
sive fungal infection that underwent T-cell depleted allogeneic
stem cell transplantation at the University of Chicago Hospitals
between 2002 and 2005. Fifteen patients had AML, three had
ALL, two had large cell lymphoma and one each had CLL or
MDS. Their median age was 52 (range 23-68). Eleven patients had
HLA-identical sibling donors, ten had unrelated or mismatched
related donors, and one had a syngeneic donor. Seventeen patients
participated in a prospective study of ﬂudarabine-melphalan-ale-
mtuzumab conditioning (J Clin Oncol 2005;23:5728). Six patients
received various other conditioning regimens containing alemtu-
zumab. Post-transplant GVHD prophylaxis was tacrolimus in all
patients. All had suffered probable or proven invasive aspergillus
infection prior to transplant, involving the lungs in twenty, and the
sinuses in two. All had received intensive antifungal treatment
prior to transplant. They continued such treatment during trans-
plant and for a prolonged period after transplant. Twenty of the 22
patients engrafted. Nine died; three from relapse and one each
from sepsis, cardiac arrest, veno-occlusive disease, fungal pneumo-
nia, PTLD, and multi-organ failure. Three patients experienced
recurrent fungal infection, with one death. Thirteen patients re-
main alive with a median follow-up for survivors of 284 days (range
274-1124). We conclude that in the modern antibiotic era, prior
invasive fungal infection should not preclude the use of stem cell
transplantation as treatment for hematologic malignancy.
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